Profile data is unavailable for this security.
About the company
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. It is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
- Revenue in USD (TTM)50.00m
- Net income in USD-54.76m
- Incorporated2023
- Employees114.00
- LocationZenas Biopharma Inc1000 Winter St, Suite 1200WALTHAM 02451United StatesUSA
- Phone+1 (857) 271-2954
- Fax+1 (302) 655-5049
- Websitehttps://zenasbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wave Life Sciences Ltd | 110.50m | -73.74m | 708.51m | 266.00 | -- | -- | -- | 6.41 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
ProKidney Corp | 0.00 | -38.68m | 712.60m | 163.00 | -- | -- | -- | -- | -0.5905 | -0.5905 | 0.00 | -7.73 | 0.00 | -- | -- | 0.00 | -27.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | 67.17 | -- | -- | -- |
Astria Therapeutics Inc | 0.00 | -93.24m | 713.78m | 59.00 | -- | 2.76 | -- | -- | -2.30 | -2.30 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -32.43 | -64.48 | -33.78 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
MBX Biosciences Inc | 0.00 | -47.20m | 718.30m | 36.00 | -- | -- | -- | -- | -1.48 | -1.48 | 0.00 | 1.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
Stoke Therapeutics Inc | 15.16m | -103.57m | 723.91m | 110.00 | -- | 2.96 | -- | 47.76 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
Savara Inc | 0.00 | -75.29m | 739.06m | 37.00 | -- | 6.10 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Annexon Inc | 0.00 | -115.16m | 742.75m | 71.00 | -- | 2.05 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
Replimune Group Inc | 0.00 | -220.01m | 745.39m | 331.00 | -- | 1.75 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Scholar Rock Holding Corp | 0.00 | -203.85m | 751.51m | 150.00 | -- | 5.62 | -- | -- | -2.22 | -2.22 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -79.66 | -38.14 | -89.70 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.2726 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
Zenas Biopharma Inc | 50.00m | -54.76m | 756.06m | 114.00 | -- | -- | -- | 15.12 | -1.38 | -1.38 | 1.26 | 4.04 | -- | -- | -- | 595,238.10 | -- | -- | -- | -- | -- | -- | -109.51 | -- | -- | -- | 0.00 | -- | -- | -- | 68.88 | -- | -- | -- |
Arbutus Biopharma Corp | 10.06m | -77.09m | 758.90m | 73.00 | -- | 6.20 | -- | 75.43 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
AbCellera Biologics Inc | 33.06m | -153.30m | 763.18m | 586.00 | -- | 0.6870 | -- | 23.09 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Rapport Therapeutics Inc | -100.00bn | -100.00bn | 776.52m | 58.00 | -- | 2.30 | -- | -- | -- | -- | -- | 9.21 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
Olema Pharmaceuticals Inc | 0.00 | -109.63m | 781.11m | 80.00 | -- | 3.44 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 793.60m | 107.00 | -- | 2.52 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |